(Fighting New Coronary Pneumonia) Russia is developing a new coronavirus vaccine that activates cellular immunity

  China News Service, Moscow, March 1 (Reporter Wang Xiujun) According to the Russian President’s website, on the 1st, the Russian Federation’s Director of Biomedicine Skovorzova revealed when reporting to Russian President Putin that Russia is developing an activation cell. Immunization of the new crown vaccine.

By vaccinating the vaccine, the immunity retention time will be longer.

  Skovorzova said that the new coronavirus vaccine being developed does not first generate humoral immunity, but instead generates cellular immunity by activating antibodies.

The advantage of cellular immunity is that immunity lasts for a long time.

Some experiments have proved that the immunity produced by cellular immunity can last for 13 to 17 years.

  Skvorcova said that this is absolutely in line with international trends.

In addition, Skovorzova mentioned that Russia is conducting clinical trials on a drug called "Peace-19" (MIR-19). This drug is absolutely safe for humans, but can effectively kill the virus and prevent it. The most serious case of the new coronavirus infection.

  Skvorcova also mentioned that the new coronavirus detection system currently used in Russia is effective for the current new coronavirus mutant.

  Humoral immunity is an immune mechanism in which plasma cells produce antibodies to achieve the purpose of protection.

Cellular immunity, also known as cell-mediated immunity, refers to the lysis and death of target cells through the secretion of perforin by effector T cells.

In the specific immune response, humoral immunity and cellular immunity not only have their own unique functions, but also can cooperate with each other to exert immune effects together.

  Currently, Russia has registered three new crown vaccines.

The first is the "Satellite-V" vaccine developed by the National Research Center for Epidemiology and Microbiology in Gamaliel, and the second is the "EpiVacCorona" vaccine developed by the "Vector" National Science Center for Virology and Biotechnology.

The third is the "Kovivac" vaccine developed by the Chumakov Federal Research and Development Center for Immunization and Biological Products.

(Finish)